Abstract
Single seizure and epilepsy is one of the most commonly encountered neurologic disorders in elderly individuals, arising as a result of complex and often multiple acquired underlying pathologies. Adenosine, acting at A1 receptors, exhibits anticonvulsant effects in experimental epilepsy and inhibits progression to status epilepticus. Adenosine deaminase is the enzyme for the regulation of adenosine levels. Therefore any change in adenosine deaminase levels will reflect to adenosine levels. Adenosine deaminase levels were decreased in the groups that were given progesterone. Progesterone may have an antiseizure effect with the additional finding decreased levels of adenosine deaminase that would have resulted in increased adenosine levels that exerts anticonvulsant effect via GABA-A receptors. Further studies are needed to evaluate the role of progesterone effects on adenosine deaminase levels and its mechanism(s) in the pathogenesis.
MeSH terms
-
Adenosine / metabolism
-
Adenosine Deaminase / drug effects*
-
Adenosine Deaminase / metabolism
-
Animals
-
Brain / drug effects*
-
Brain / enzymology*
-
Brain / physiopathology
-
Convulsants / pharmacology
-
Disease Models, Animal
-
Epilepsy / drug therapy*
-
Epilepsy / enzymology*
-
Epilepsy / physiopathology
-
Female
-
Male
-
Mice
-
Pentylenetetrazole / pharmacology
-
Polyunsaturated Alkamides / metabolism
-
Polyunsaturated Alkamides / pharmacology
-
Polyunsaturated Alkamides / therapeutic use
-
Progesterone / metabolism
-
Progesterone / pharmacology*
-
Progesterone / therapeutic use
-
Propionates / metabolism
-
Propionates / pharmacology
-
Propionates / therapeutic use
-
Receptor, Adenosine A1 / drug effects
-
Receptor, Adenosine A1 / metabolism
-
Receptors, GABA-A / drug effects
-
Receptors, GABA-A / metabolism
Substances
-
Convulsants
-
Polyunsaturated Alkamides
-
Propionates
-
Receptor, Adenosine A1
-
Receptors, GABA-A
-
Progesterone
-
3,4-dichlorophenyl propenylisobutylamide
-
Adenosine Deaminase
-
Adenosine
-
Pentylenetetrazole